Andrea Mazzanti

List of Publications by Citations

72 papers	4,570 citations	24 h-index	67 g-index
96 ext. papers	6,282 ext. citations	6.2 avg, IF	4.91 L-index

#	Paper	IF	Citations
72	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of	9.5	2187
71	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology	3.9	426
70	Long-term follow-up of patients with short QT syndrome. *Journal of the American College of Cardiology*, **2011**, 58, 587-95	15.1	226
69	Novel insight into the natural history of short QT syndrome. *Journal of the American College of Cardiology*, **2014**, 63, 1300-1308	15.1	147
68	Dilated cardiomyopathy. *Nature Reviews Disease Primers*, **2019**, 5, 32	51.1	143
67	Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis. *Circulation*, **2016**, 133, 622-30	16.7	138
66	Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. *Journal of the American College of Cardiology*, **2016**, 67, 1053-1058	15.1	123
65	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. *European Heart Journal*, **2020**, 41, 1414-1429	9.5	110
64	Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk. *Journal of the American College of Cardiology*, **2016**, 68, 2540-2550	15.1	99
63	Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. *International Journal of Cardiology*, **2020**, 319, 106-114	3.2	89
62	Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. *Circulation*, **2020**, 141, 1872-1884	16.7	80
61	Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. *Journal of the American College of Cardiology*, **2018**, 71, 1663-1671	15.1	76
60	Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome. *International Journal of Cardiology*, **2015**, 190, 393-402	3.2	43
59	Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome. *Journal of the American College of Cardiology*, **2017**, 70, 3010-3015	15.1	41
58	Phenotype and prognostic correlations of the converter region mutations affecting the myosin heavy chain. *Heart*, **2015**, 101, 1047-53	5.1	34
57	Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (). *Circulation Research*, **2017**, 121, 525-536	15.7	33
56	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. *Journal of the American College of Cardiology*, **2019**, 73, 1756-1765	15.1	33

55	The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases. *Expert Review of Cardiovascular Therapy*, **2014**, 12, 499-519	2.5	31
54	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. *Revista Espanola De Cardiologia (English Ed)*, **2016**, 69, 176	0.7	30
53	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. *Circulation*, **2020**, 142, 324-338	16.7	27
52	Usefulness of exercise test in the diagnosis of short QT syndrome. *Europace*, **2015**, 17, 628-34	3.9	27
51	Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation. *Circulation Research*, **2019**, 124, 539-552	15.7	27
50	Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. *Circulation*, **2020**, 142, 513-515	16.7	26
49	Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia. *Heart Lung and Circulation*, **2016**, 25, 777-83	1.8	26
48	The Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT Syndrome. *JACC: Clinical Electrophysiology*, **2017**, 3, 727-743	4.6	24
47	From decision to shared-decision: Introducing patientsTpreferences into clinical decision analysis. *Artificial Intelligence in Medicine*, **2015**, 65, 19-28	7.4	21
46	The new kids on the block of arrhythmogenic disorders: Short QT syndrome and early repolarization. *Journal of Cardiovascular Electrophysiology*, **2017**, 28, 1226-1236	2.7	18
45	Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1. *Journal of the American College of Cardiology*, **2020**, 75, 1772-1784	15.1	18
44	Big Data as a Driver for Clinical Decision Support Systems: A Learning Health Systems Perspective. *Frontiers in Digital Humanities*, **2018**, 5,	2.1	16
43	An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. *Circulation*, **2020**, 141, 429-439	16.7	15
42	Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome. *Heart Rhythm*, **2019**, 16, 1468-1474	6.7	14
41	Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria. *Journal of Cardiovascular Electrophysiology*, **2016**, 27, 937-43	2.7	14
40	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. *Genetics in Medicine*, **2021**, 23, 47-58	8.1	13
39	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of -Catecholaminergic Polymorphic Ventricular Tachycardia. *Circulation*, **2020**, 142, 932-947	16.7	12
38	Gu ESC 2015 sobre el tratamiento de pacientes con arritmiasventriculares y prevenci de la muerte s bita cardiaca. *Revista Espanola De Cardiologia*, **2016**, 69, 176.e1-176.e77	1.5	11

37	UceWeb: a web-based collaborative tool for collecting and sharing quality of life data. *Methods of Information in Medicine*, **2015**, 54, 156-63	1.5	11
36	CardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases. *Human Mutation*, **2018**, 39, 1835-1846	4.7	11
35	Gquest: modeling patient questionnaires and administering them through a mobile platform application. *Computer Methods and Programs in Biomedicine*, **2014**, 117, 277-91	6.9	10
34	Graphical representation of life paths to better convey results of decision models to patients. *Medical Decision Making*, **2015**, 35, 398-402	2.5	9
33	The interpretation of genetic tests in inherited cardiovascular diseases. *Neurology International*, **2011**, 1, 8	0	9
32	2015 ESC GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH VENTRICULAR ARRHYTHMIAS AND THE PREVENTION OF SUDDEN CARDIAC DEATH. *Russian Journal of Cardiology*, **2016**, 5-86	1.3	8
31	Genetic causes of sudden cardiac death in the young. *Current Opinion in Cardiology*, **2017**, 32, 253-261	2.1	7
30	Genetic causes of sudden cardiac death in children: inherited arrhythmogenic diseases. *Current Opinion in Pediatrics*, **2017**, 29, 552-559	3.2	7
29	Is There a Role for Genetics in the Prevention of Sudden Cardiac Death?. *Journal of Cardiovascular Electrophysiology*, **2016**, 27, 1124-32	2.7	6
28	Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the Gene Associated With Brugada Syndrome. *Frontiers in Physiology*, **2020**, 11, 616819	4.6	6
27	Efficacy and Limitations of Quinidine in Patients With Brugada Syndrome. *Circulation: Arrhythmia and Electrophysiology*, **2019**, 12,	6.4	5
26	Genetic risk stratification in cardiac arrhythmias. *Current Opinion in Cardiology*, **2018**, 33, 298-303	2.1	4
25	Sudden death in lambda light chain AL cardiac amyloidosis: a review of literature and update for clinicians and pathologists. *International Journal of Clinical and Experimental Pathology*, **2020**, 13, 1474-1482	1.4	4
24	Arrhythmic Mitral Valve Prolapse: Introducing an Era of Multimodality Imaging-Based Diagnosis and Risk Stratification. *Diagnostics*, **2021**, 11,	3.8	4
23	Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: JACC Focus Seminar 5/5. *Journal of the American College of Cardiology*, **2021**, 77, 2592-2612	15.1	4
22	Unexpected Risk Profile of a Large Pediatric Population With Brugada Syndrome. *Journal of the American College of Cardiology*, **2019**, 73, 1868-1869	15.1	3
21	Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With Blockers.. *JAMA Cardiology*, **2022**,	16.2	3
20	Conduction disorder and primary cardiac tumor: a fatal case of multiple lipomas of the right atrium. *Journal of Geriatric Cardiology*, **2019**, 16, 431-433	1.7	2

19	Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients. *Frontiers in Pharmacology*, **2020**, 11, 580481	5.6	2
18	Outcomes and management of arrhythmogenic right ventricular cardiomyopathy in pregnancy: a case report. *European Heart Journal - Case Reports*, **2019**, 3, 1-5	0.9	2
17	Reply: Did Mutation Type Affect the Efficacy´of Mexiletine Observed in Patients With LQTS Type 3?. *Journal of the American College of Cardiology*, **2017**, 69, 248-249	15.1	1
16	Risk Stratification in the Long QT Syndrome. *Cardiac Electrophysiology Clinics*, **2012**, 4, 53-60	1.4	1
15	Short QT Syndromes. *Cardiac Electrophysiology Clinics*, **2010**, 2, 551-558	1.4	1
14	Novel insights on Andersen-Tawil syndrome type 1. *European Heart Journal*, **2020**, 41,	9.5	1
13	Safety and efficacy of catheter ablation for ventricular tachycardia in elderly patients with structural heart disease: a systematic review and meta-analysis. *Journal of Interventional Cardiac Electrophysiology*, **2021**, 1	2.4	1
12	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk): comment-AuthorsTreply.. *Europace*, **2022**,	3.9	1
11	Is mexiletine ready for prime time in patients with Type 2 Long QT Syndrome?. *European Heart Journal*, **2020**, 41,	9.5	1
10	Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). *Europace*, **2021**,	3.9	1
9	Los estudios gen□icos en la prevenci□ de la muerte s□bita: ¿realidad o ficci□?. *Cardiocore*, **2012**, 47, 50-53		0
8	Outcomes of manual versus remote magnetic navigation for catheter ablation of ventricular tachycardia: a systematic review and updated meta-analysis. *PACE - Pacing and Clinical Electrophysiology*, **2021**, 44, 1102-1114	1.6	0
7	Genotype-Phenotype Correlation of Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003222	5.2	0
6	Identification of a SCN5A founder mutation causing sudden death, Brugada syndrome, and conduction blocks in Southern Italy. *Heart Rhythm*, **2021**, 18, 1698-1706	6.7	0
5	Diagn□tico del s□drome de QT largo: valor del ortostatismo. *Revista Espanola De Cardiologia*, **2017** , 70, 898-900	1.5	
4	Catecholaminergic Polymorphic Ventricular Tachycardia **2022**, 167-183		
3	Inherited Arrhythmias: LQTS/SQTS/CPVT **2018**, 413-435		
2	Genetics of Long QT and Short QT Syndromes1-6		

1	Programmed electrophysiological stimulation for risk prediction in patients with Brugada syndrome: closing time?. *Revista Espanola De Cardiologia (English Ed)*, **2021**, 75, 545-545	0.7